Government grants are reshaping primary care, improving services, and benefitting both practitioners and patients. Explore the impact of this funding initiative.
CREDIT: This is an edited version of an article that originally appeared on Care Home Professional
The UK government has earmarked over £4 million to assist English councils in handling inspections by the Care Quality Commission (CQC). As part of this effort, the CQC is implementing a new inspection framework, currently undergoing trials in several local authorities, including Birmingham, Lincolnshire, North Lincolnshire, Nottingham, and Suffolk.
Financial assistance for initial inspections
The £4.1 million fund is intended to aid local authorities as they prepare for their initial inspections under the new framework. Each English local authority will receive a portion of the fund, amounting to approximately £26,730 per authority.
Easing the burden
A statement on the government’s official website explains the purpose of this non-recurring grant: “The purpose of this non-repeating grant is to provide support to local authorities in England towards expenditure lawfully incurred or to be incurred by the new burden of engaging with CQC review and assessment for the first time. This includes the time and resources needed for local authorities to familiarise themselves with and effectively engage with their first formal assessment.”
Meeting new obligations
The CQC’s duty to review and assess local authorities’ delivery of their functions related to adult social care, as outlined in the Care Act 2014, began in April 2023. This grant, amounting to £4.1 million, aims to facilitate local authorities in fulfilling their obligations effectively.
Implications for primary care
As primary care and practice business managers navigate the evolving landscape of healthcare regulations, funding such as the £4 million grant from the UK government becomes crucial. This financial support not only aids in the preparations for inspections but also alleviates the burden on local authorities. As they adapt to the new inspection framework, it is essential for practice business managers to stay informed and stay up to date with the latest developments in the sector.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events relating to CSL Seqirus products should also be reported to Seqirus UK Limited on 01748 828816.
1. Seqirus Data on File, August 2023. SREF–17994. 2. Adjuvanted Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics. 3. Cell-based Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.
Be the first to comment